Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Somaxon Pharmaceuticals

Request full access

Growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription

Solana Beach, United StatesFounded 2003Biotech & Life Sciences

About Somaxon Pharmaceuticals

Somaxon Pharmaceuticals, Inc. operated as a specialty pharmaceutical company from its inception in August 2003 until its acquisition in 2013. The San Diego-based firm was co-founded by David F. Hale, a serial entrepreneur with extensive experience in founding and developing life sciences companies, and Kenneth M. Cohen, who served as the initial President and CEO. Cohen brought significant pharmaceutical industry experience, including managing the historic launch of Prozac during his tenure at Eli Lilly and Company. Hale, who served as Chairman, had a long history of leadership roles at companies like Hybritech and CancerVax.

The company's business model centered on in-licensing, developing, and commercializing proprietary branded pharmaceutical products targeting the central nervous system (CNS) therapeutic area. Somaxon's strategy involved identifying late-stage product candidates that could be repurposed or reformulated for new uses, thereby aiming for a more streamlined development and regulatory path. The company went public with an IPO on December 15, 2005, raising capital to advance its clinical programs.

Somaxon's lead product was Silenor® (doxepin), a prescription drug for the treatment of insomnia characterized by difficulty with sleep maintenance. The product's distinction lay in its use of a very low dose of doxepin, a tricyclic antidepressant that has been available for decades at much higher doses. This low-dose formulation was designed to selectively target histamine receptors to improve sleep without causing the significant next-day residual effects or abuse potential associated with many other sleep aids. The U.S. Food and Drug Administration (FDA) granted approval for Silenor in March 2010, a major milestone for the company following two previous rejections. Revenue was generated through the commercial sales of Silenor to patients with insomnia.

In December 2012, Pernix Therapeutics Holdings, Inc. announced a definitive agreement to acquire Somaxon in a stock-for-stock transaction valued at approximately $25 million. The acquisition was completed in March 2013, marking the end of Somaxon's operations as an independent entity and the integration of Silenor into Pernix's product portfolio.

Source: Dealroom company data

Somaxon Pharmaceuticals in the Solana Beach ecosystem

Live from Dealroom

The Somaxon Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • Domain Associates
  • Scale Venture Partners
  • Windamere Venture Partners
  • CDIB BioScience Ventures
  • Montreux Equity Partners

Series B and later1 investor entered at this stage

  • MPM BioImpact
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Solana Beach HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Somaxon Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Somaxon Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.